Your browser is no longer supported. Please, upgrade your browser.
Settings
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.10% Shs Outstand45.97M Perf Week1.54%
Market Cap604.51M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float43.79M Perf Month-16.24%
Income-14.30M PEG- EPS next Q-0.13 Inst Own90.40% Short Float4.53% Perf Quarter-17.03%
Sales159.10M P/S3.80 EPS this Y56.10% Inst Trans1.87% Short Ratio3.09 Perf Half Y-4.71%
Book/sh2.91 P/B4.52 EPS next Y31.00% ROA-6.90% Target Price20.00 Perf Year-23.55%
Cash/sh3.04 P/C4.32 EPS next 5Y15.70% ROE-11.00% 52W Range11.90 - 18.99 Perf YTD-17.55%
Dividend- P/FCF- EPS past 5Y-3.50% ROI-14.20% 52W High-30.75% Beta1.35
Dividend %- Quick Ratio2.40 Sales past 5Y36.10% Gross Margin88.50% 52W Low10.50% ATR0.64
Employees142 Current Ratio2.40 Sales Q/Q7.30% Oper. Margin-9.70% RSI (14)32.90 Volatility2.72% 5.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-926.00% Profit Margin-9.00% Rel Volume0.52 Prev Close13.05
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume641.59K Price13.15
Recom2.00 SMA20-8.33% SMA50-18.54% SMA200-14.09% Volume336,776 Change0.77%
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Mar-10-10Initiated Hapoalim Outperform $23
Feb-17-10Reiterated Jefferies & Co Buy $22 → $20
Dec-09-09Initiated Jefferies & Co Buy $22
Jul-29-08Downgrade JP Morgan Overweight → Neutral
Jul-29-08Downgrade Banc of America Sec Buy → Neutral
Jul-28-08Downgrade Caris & Company Buy → Above Average $22 → $3
May-02-08Initiated Caris & Company Buy $22
Nov-09-07Reiterated Friedman Billings Outperform $31 → $16
Nov-01-07Reiterated Friedman Billings Outperform $37 → $31
Sep-10-07Initiated Banc of America Sec Buy
May-08-07Initiated Citigroup Hold
May-01-07Reiterated Friedman Billings Outperform $40 → $37
Feb-14-07Initiated Friedman Billings Outperform $40
Nov-13-17 09:00AM  Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences PR Newswire
Nov-10-17 04:05PM  Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia PR Newswire
12:03PM  Edited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:14PM  Vanda reports 3Q loss Associated Press -5.08%
04:01PM  Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire
12:30PM  Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Oct-27-17 11:20AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 27, 2017 Capital Cube
Oct-24-17 05:00PM  Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017 PR Newswire
Oct-17-17 10:03AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 17, 2017 Capital Cube
Oct-10-17 06:15PM  Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference PR Newswire
08:25AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017 Capital Cube
Oct-02-17 11:10AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
09:15AM  Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch PR Newswire
Sep-29-17 01:00PM  Vanda to Present Scientific Posters at World Sleep 2017 PR Newswire
09:00AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-19-17 07:31AM  These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Motley Fool
Sep-14-17 10:25AM  Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)? Simply Wall St.
10:06AM  Summit Therapeutics Stock Gets Smoked After IPO Pricing TheStreet.com
Sep-13-17 04:49PM  Vanda Pharma shares decline as goal of itch drug study not reached MarketWatch
04:04PM  Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis PR Newswire
Sep-11-17 05:00PM  Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences PR Newswire
Sep-06-17 05:00PM  Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference PR Newswire
Sep-01-17 09:56AM  Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-29-17 08:46AM  Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice Zacks
Aug-28-17 11:01AM  Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR Zacks
Aug-25-17 10:43AM  5 Efficient Stocks to Buy for a Healthy Portfolio Zacks
Aug-23-17 08:55AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : August 23, 2017 Capital Cube
Aug-21-17 07:52PM  Vanda Pharmaceuticals, Inc. Value Analysis (NASDAQ:VNDA) : August 21, 2017 Capital Cube
Aug-16-17 08:30AM  Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Zacks
Aug-09-17 09:20AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : August 9, 2017 Capital Cube
Aug-04-17 04:29PM  Vanda Pharmaceuticals preps for jet lag study results later this year American City Business Journals
Aug-02-17 05:41PM  Vanda reports 2Q loss Associated Press
04:01PM  Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
10:10AM  Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Jul-21-17 07:00AM  Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia PR Newswire
Jul-17-17 09:00AM  Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 PR Newswire
Jul-14-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
Jun-21-17 08:30AM  Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% Zacks
08:06AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : June 21, 2017 Capital Cube
Jun-05-17 05:00PM  Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences PR Newswire
May-30-17 02:35PM  Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-22-17 08:37AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017 Capital Cube
May-09-17 08:54AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017 Capital Cube
May-05-17 04:41PM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017 Capital Cube
12:21PM  Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 05:09PM  Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer American City Business Journals
10:20AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-02-17 06:10PM  Vanda reports 1Q loss Associated Press
04:01PM  Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
08:35AM  Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call Accesswire
May-01-17 05:45PM  Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference PR Newswire
Apr-20-17 03:24PM  Vanda Pharmaceuticals, Inc. Value Analysis (NASDAQ:VNDA) : April 20, 2017 Capital Cube
Apr-19-17 08:14AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April 19, 2017 Capital Cube
Apr-13-17 04:45PM  Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 PR Newswire
Mar-31-17 08:33AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017 Capital Cube
08:33AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017
Mar-29-17 05:40PM  Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors PR Newswire
Mar-21-17 08:16AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 21, 2017
Mar-13-17 05:23PM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-07-17 07:17AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017 Capital Cube
07:17AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017
Mar-06-17 04:07PM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:05PM  Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences PR Newswire
Feb-22-17 01:04PM  VANDA PHARMACEUTICALS INC. Financials
11:22AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Capital Cube
11:22AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
Feb-21-17 07:10AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : February 21, 2017 Capital Cube
07:10AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : February 21, 2017
Feb-17-17 07:04AM  VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
Feb-15-17 06:20PM  Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
05:26PM  Vanda reports 4Q loss Associated Press
04:30PM  Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:26PM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close
Jan-19-17 04:30PM  Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017 PR Newswire
Jan-17-17 02:39PM  Merck KGaA Expands Distribution Deal with Roche (revised) -5.61%
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com -5.41%
Jan-10-17 08:35AM  Jefferies Has 5 Top Biotech Stocks to Buy for 2017
Jan-09-17 07:07AM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
07:00AM  Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance PR Newswire
Jan-02-17 08:13AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : January 2, 2017
07:40AM  Abbott Labs to Close St. Jude Acquisition Later this Week
Dec-30-16 09:52AM  Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
09:37AM  Prima (PBMD) Reports Favorable Initial Melanoma Study Data Zacks
Dec-28-16 10:18AM  Shire Gets FDA Approval for Label Expansion of Adynovate
07:52AM  Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold
Dec-27-16 09:13AM  Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
08:43AM  Why Vanda Pharmaceuticals (VNDA) Might Be a Diamond in the Rough
Dec-23-16 08:25AM  Roche (RHHBY) Hemophilia A Drug Positive in Phase III
08:16AM  Teva Settles Foreign Bribery Charges with U.S. Government
Dec-22-16 06:18PM  Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx
07:59AM  Incyte/Merus Ink Collaboration for Bispecific Antibodies
Dec-21-16 06:19PM  Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU
10:05AM  Vanda Pharmaceuticals, Inc. Value Analysis (NASDAQ:VNDA) : December 21, 2016
09:00AM  J&J Files for FDA Approval of Simponi Aria Label Expansion
08:41AM  Biogen (BIIB) Board Okays Hemophilia Business Spin-off
Dec-20-16 08:53AM  Conatus Stock Up on Liver Drug Collaboration with Novartis
07:19AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : December 20, 2016
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gulino Richard L.SVP, General Counsel & Sec.Jan 03Sale15.5110,900169,0909,100Jan 05 05:07 PM
Kelly James PatrickSVP, CFO & TreasurerJan 03Sale15.5110,895169,01369,721Jan 05 05:01 PM
Polymeropoulos Mihael HristosPresident and CEOJan 03Sale15.4823,330361,242850,848Jan 05 04:58 PM